Mohammad Hussain, MD

Hematologist/Oncologist

Cancer Care

Accepting new patients

Call for an appointment

217-545-8000

I am a:

Request appointment

Language:

English

About me

Gender

Male

Education & training

Positions

Assistant Professor

Board Certifications

Internal Medicine

Medical Oncology

Hematology

Medical School

Allama Iqbal Medical College University of Punjab, Pakistan

Residency

Pinnacle Health Hospitals, Harrisburg, PA (UPMC)

Fellowship

Hematology and Oncology, Levine Cancer Institute, Charlotte, NC and Blood and Marrow Transplant, Stanford University School of Medicine

Specialties

Cancer Care

Conditions

Appointments

SIU Medicine strongly encourages all patients to verify coverage, benefits and which providers are considered in-network with their health plan. SIU Medicine has more than 300 health care providers ready to serve you and your family. SIU Medicine accepts a wide variety of governmental and non-governmental health plans to serve our community.

Request an appointment

Clinical locations

Locations

SIU Medicine Hematology and Oncology | Simmons Cancer Institute

315 W. Carpenter St. Springfield, IL 62702 1st Floor, Clinic B

Get Directions

Mon - Fri: 8:00 am-4:30 pm

Hospital privileges

HSHS St. John's Hospital, Springfield, IL
Memorial Health, Springfield IL

Clinical trials

Trial

Simmons Cancer Institute

KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Active recruiting

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Trial

Simmons Cancer Institute

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Active recruiting

The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .